Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline

CNBC spoke with 11 current and former Pfizer employees, who asked to remain anonymous, about Pfizer’s dizzying climb, rapid decline and turnaround strategy.